Cynata Therapeutics Limited ( (AU:CYP) ) has issued an announcement. Cynata Therapeutics Limited announced it received a $1.7 million R&D Tax Incentive Refund for the 2024/2025 financial year. This ...

Unlock the advantage of pragmatic trials and improve efficiency and real-world relevance to reduce risk and strengthen ...

Mesoblast’s Ryoncil ® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved ...

Updated clinical data from the Phase 1/2 ABILITY-1 Study evaluating MDNA11, an emerging best-in-class IL-2 therapy, as a monotherapy and in combination with pembrolizumab, will be presented by Dr.

Stigma, late diagnosis, and patchy access keep Europe from its HIV milestones. What will it take to close the gap?

People with a meniscal tear and osteoarthritis prescribed home exercises with or without physical therapy reported ...

CD19 chimeric antigen receptor T-cell therapy improved lung function and skin thickness in patients with severe refractory ...

The group's statement on access to contraception was updated to reflect the patchwork contraceptive landscape in the wake of ...

Mina is a molecular biology major and plans to become an oncologist, with a focus on improving access to care.

NRG Therapeutics Ltd. (“NRG”), an innovative neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, is pleased to announce expansion of its team with the addition of ...

People with a meniscal tear and osteoarthritis prescribed home exercises with or without physical therapy reported ...

The complications highlight pregnancy as a crucial life opportunity for CV health optimization, said investigators led by ...